Michael Millward
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Research top 1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 116
- Cancer Immunotherapy and Biomarkers 43
- Lung Cancer Research Studies 20
- Cancer Treatment and Pharmacology 18
- Cutaneous Melanoma Detection and Management 14
-
- Cancer Genomics and Diagnostics 27
- Co-authors
- Elin Solomonovna Gray (35 shared papers)Mel R. Ziman (24 shared papers)Georgina Venetia Long (14 shared papers)Richard F. Kefford (10 shared papers)Anna K. Nowak (22 shared papers)Anna C. Pavlick (6 shared papers)Jeffrey R. Infante (4 shared papers)Tarek M. Meniawy (23 shared papers)
- Journals
- Annals of Oncology (31 papers)European Journal of Cancer (13 papers)Lung Cancer (12 papers)Clinical Cancer Research (10 papers)British Journal of Cancer (8 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Michael Millward
236 papers receiving 12.5k citations
Michael Millward's Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 6.4k
- Cancer Research 1.5k
- Immunology 1.7k
- Molecular Biology 5.6k
- Pulmonary and Respiratory Medicine 2.1k
Countries citing papers authored by Michael Millward
This map shows the geographic impact of Michael Millward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Millward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Millward more than expected).
Fields of papers citing papers by Michael Millward
This network shows the impact of papers produced by Michael Millward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Millward. The network helps show where Michael Millward may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Millward, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 243 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1551 |
| 2 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1129 |
| 3 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Hit paper breakdown → | 2012 | 809 |
| 4 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Hit paper breakdown → | 2017 | 536 |
| 5 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2020 | 407 |
| 6 | 2012 | 405 | |
| 7 | 2015 | 286 | |
| 8 | 2017 | 194 | |
| 9 | 2005 | 181 | |
| 10 | 2019 | 177 | |
| 11 | 1997 | 168 | |
| 12 | 2013 | 157 | |
| 13 | 2011 | 143 | |
| 14 | 2012 | 133 | |
| 15 | 2011 | 132 | |
| 16 | 2016 | 130 | |
| 17 | 1998 | 130 | |
| 18 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 Hit paper breakdown → | 2023 | 126 |
| 19 | 1993 | 124 | |
| 20 | 2009 | 123 |
About Michael Millward
Michael Millward is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Molecular Biology, having authored 243 papers that have together received 12.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (43 papers), Cancer Genomics and Diagnostics (27 papers), Lung Cancer Treatments and Mutations (25 papers), Melanoma and MAPK Pathways (21 papers), Lung Cancer Research Studies (20 papers), Cancer Treatment and Pharmacology (18 papers), Occupational and environmental lung diseases (14 papers) and Cutaneous Melanoma Detection and Management (14 papers). The work is most often cited by research in Oncology (6.4k citations), Cancer Research (1.5k citations), Immunology (1.7k citations), Molecular Biology (5.6k citations) and Pulmonary and Respiratory Medicine (2.1k citations). Michael Millward has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Elin Solomonovna Gray, Mel R. Ziman, Georgina Venetia Long, Richard F. Kefford, Anna K. Nowak, Anna C. Pavlick, Jeffrey R. Infante, Tarek M. Meniawy, Kevin B. Kim and Danièle Ouellet. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Lung Cancer, Clinical Cancer Research and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.